We assign a fundamental rating of 2 out of 10 to IMV. IMV was compared to 525 industry peers in the Biotechnology industry. IMV may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, IMV is valued expensive at the moment.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

IMV had negative earnings in the past year.
In the past year IMV has reported a negative cash flow from operations.

1.2 Ratios

IMV has negative profitability rations, so we won't be analyzing them here.

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IMV so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

IMV does not have a ROIC to compare to the WACC, probably because it is not profitable.
IMV has more shares outstanding than it did 1 year ago.
IMV has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -12.68, we must say that IMV is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -12.68, IMV is doing worse than 82.15% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-12.68

ROIC/WACCN/A

WACC6.97%

2.3 Liquidity

IMV has a Current Ratio of 2.93. This indicates that IMV is financially healthy and has no problem in meeting its short term obligations.
IMV's Current ratio of 2.93 is on the low side compared to the rest of the industry. IMV is outperformed by 71.88% of its industry peers.
IMV has a Quick Ratio of 2.93. This indicates that IMV is financially healthy and has no problem in meeting its short term obligations.
IMV has a worse Quick ratio (2.93) than 70.46% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.93
Quick Ratio	2.93

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 4.44% over the past year.
IMV shows a strong growth in Revenue. In the last year, the Revenue has grown by 37.21%.
The Revenue has been growing by 14.12% on average over the past years. This is quite good.

EPS 1Y (TTM)4.44%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%29.29%

Revenue 1Y (TTM)37.21%

Revenue growth 3Y-8.54%

Revenue growth 5Y14.12%

Sales Q2Q%337.14%

3.2 Future

Based on estimates for the next years, IMV will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.36% on average per year.
IMV is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 162.00% yearly.

EPS Next Y20.34%

EPS Next 2Y22.41%

EPS Next 3Y17.34%

EPS Next 5Y15.36%

Revenue Next Year-80.66%

Revenue Next 2Y59.28%

Revenue Next 3Y71.75%

Revenue Next 5Y162%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IMV. In the last year negative earnings were reported.
Also next year IMV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.